Jan 12 · 11:29:00 AM · Source: Company News

Biogen Idec announced today the submission of a marketing authorization application (MAA) to the European Medicines Agency for Fampridine Prolonged Release (Fampridine-PR) tablets, a novel oral therapy for the improvement of walking ability in adult patients with multiple sclerosis (MS). The company also has filed a New Drug Submission (NDS) to Health Canada.

Track · email · face · Twitter · digg · COMMENTS
by Larry Etter